We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
23 March 2017
Collagen Solutions Plc
(the "Company" or the "Group")
UK Investor Show 2017 attendance
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics will be participating in the UK Investor Show which will be taking place on 1 April 2017 at the Queen Elizabeth II Conference Centre in Westminster, London SW1P 3EE. The Senior Management will be available from 8:30am until 5:30pm to discuss recent positive events for the Company as well as their strategy for accelerating growth. The Collagen team at the show will be led by David Evans, the Chairman of Collagen Solutions, who will be presenting to the investor audience "A Chairman's Story", his view of where the Company has come from, what it has achieved to-date and why it has such a pivotal position in the rapidly growing regenerative medicine market. You will find Collagen Solutions at Booth 65 where the management will be available to discuss the opportunities the Company has and answer any questions you may have.
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For additional information, please visit www.collagensolutions.com.
Enquiries:
Collagen Solutions Plc Contact via Walbrook Jamal Rushdy, Chief Executive Officer Gill Black, Chief Financial Officer Cenkos Securities plc (Nominated Tel: 0207 397 8900 Adviser and Broker) Stephen Keys Steve Cox Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com Mike Wort Mob: 07900 608 002 Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKBDBPBKDBNB
(END) Dow Jones Newswires
March 23, 2017 03:01 ET (07:01 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
